Saffron for Mood and Depression

Of all the health uses claimed for saffron, depression is where the human evidence is genuinely strong. Since the early 2000s, more than a dozen randomized, double-blind, placebo-controlled trials have tested standardized saffron — usually about 30 mg per day — in adults with mild-to-moderate depression. Several went further and compared saffron directly against standard antidepressants such as fluoxetine (Prozac), imipramine, citalopram, and sertraline (Zoloft). Across these studies, saffron consistently beat placebo and generally performed about as well as the comparison drug over six to eight weeks, and multiple independent meta-analyses have reached the same conclusion. This page walks through that evidence honestly, including its real limitations — and it is emphatic on one point: encouraging trial results are never a reason to stop a prescribed antidepressant on your own.

Table of Contents

  1. Saffron's Strongest Evidence Base
  2. The Active Compounds: Crocin, Crocetin, Safranal
  3. How Saffron May Lift Mood
  4. Saffron vs Placebo: The Randomized Trials
  5. Head-to-Head With Antidepressants
  6. What the Meta-Analyses Show
  7. Add-On Use and SSRI Side Effects
  8. Standardized Extracts and Newer Trials
  9. Practical Use, Dose, and Timing
  10. Honest Limitations of the Evidence
  11. Important Cautions
  12. Key Research Papers
  13. Connections
  14. Featured Videos

Saffron's Strongest Evidence Base

Most herbal remedies rest on tradition, test-tube data, and a scattering of small studies. Saffron is unusual: for depression it has been put through the same kind of testing used for pharmaceutical drugs — randomized allocation, double-blinding (neither patient nor researcher knew who got saffron), a placebo or active-drug comparison group, and validated depression rating scales such as the Hamilton Depression Rating Scale (HAM-D) and the Beck Depression Inventory (BDI).

The reason so much of this research came out of Iran is simple: Iran grows roughly 90 percent of the world's saffron, and academic groups there — most prominently the team led by Shahin Akhondzadeh at Tehran University of Medical Sciences — had both the material and the interest to study it rigorously. Their early trials, published in respected international journals from 2004 onward, opened a field that later expanded to Australia, Europe, and elsewhere.

The overall picture that emerged is consistent: in adults with mild-to-moderate depression, standardized saffron at about 30 mg per day reduces depression scores significantly more than placebo, and about as much as a starting dose of a standard antidepressant. That is a stronger, more replicated result than almost any other botanical can claim for a mental-health condition — with the important caveat that "mild-to-moderate" is doing real work in that sentence. Saffron has not been shown to treat severe or treatment-resistant depression, and it has not been tested as a substitute for antidepressants in people who are already stable on them.

Back to Table of Contents

The Active Compounds: Crocin, Crocetin, Safranal

Saffron threads are the dried stigmas of the flower Crocus sativus. Their color, bitterness, and aroma come from three families of compounds, all of which have been studied for mood effects:

In practice, commercial saffron supplements are usually standardized to a guaranteed content of these markers (for example, a minimum percentage of crocins, or a fixed amount of "safranal equivalents") so that each dose delivers a consistent amount of active compound. That standardization is part of why the depression trials are comparable to one another and is discussed further on the sources, dosing, and safety page.

Back to Table of Contents

How Saffron May Lift Mood

No one claims the mechanism is fully understood, but several plausible and partly overlapping pathways have emerged from laboratory and animal research, summarized in mechanistic reviews such as Lopresti and Drummond (2014) and Matraszek-Gawron and colleagues (2022):

  1. Monoamine reuptake. Crocin and safranal appear to modestly inhibit the reuptake of serotonin, dopamine, and norepinephrine — the same broad target as many conventional antidepressants, though saffron's effect in the test tube is weaker and less selective.
  2. Anti-inflammatory action. Depression is associated in many patients with elevated inflammatory markers. Saffron compounds reduce pro-inflammatory cytokines such as TNF-alpha and interleukin-6 in laboratory models, which may be relevant to the "inflammatory" subtype of depression.
  3. Antioxidant and neuroprotective effects. As carotenoids, crocin and crocetin quench reactive oxygen species and may protect neurons from oxidative damage, supporting healthier synaptic function.
  4. Stress-axis and neurotrophic effects. Some animal work suggests saffron dampens an overactive stress (HPA-axis) response and supports brain-derived neurotrophic factor (BDNF), a protein tied to resilience and recovery in mood disorders.

The honest caveat is that most of this mechanistic detail comes from cells and rodents, not from people. What the human trials show is a clinical effect on depression scores; the mechanisms above are the leading explanations for that effect, not proven causes of it.

Back to Table of Contents

Saffron vs Placebo: The Randomized Trials

The placebo-controlled trials are the foundation of saffron's reputation. Two are worth describing in detail because they set the template:

Akhondzadeh and colleagues (2005), Phytotherapy Research. Forty adults with mild-to-moderate depression were randomized to saffron 30 mg per day (as a stigma extract, 15 mg twice daily) or an identical-looking placebo for six weeks. The saffron group improved significantly more on the Hamilton Depression Rating Scale than the placebo group, and side effects were mild and no more common than with placebo.

Moshiri and colleagues (2006), Phytomedicine. This trial tested the petals of the saffron flower (a cheaper part of the plant than the prized stigma) at 30 mg per day against placebo over six weeks, again in mild-to-moderate depression. The petal extract also beat placebo, suggesting the antidepressant compounds are not confined to the costly red threads alone.

Subsequent placebo-controlled studies broadly reproduced this pattern in different populations, and it is this consistency — the same direction of effect, across independent research groups — that gives the placebo comparison its weight.

Back to Table of Contents

Head-to-Head With Antidepressants

What separates saffron from most "natural mood support" products is that it has been tested directly against prescription antidepressants, not only against placebo:

The recurring theme across these trials is non-inferiority: saffron did not clearly outperform the drugs, but it kept pace with a standard starting dose while generally causing fewer side effects. It is important to read this correctly. "As good as a low dose of an SSRI over six weeks in mild-to-moderate depression" is a meaningful finding, but it is not the same as "as good as antidepressants for everyone." These were small, short studies in carefully selected patients, and none tested saffron in severe depression or over the many months that antidepressant treatment often lasts.

Back to Table of Contents

What the Meta-Analyses Show

When many small trials point the same way, meta-analysis pools them to estimate the overall effect. Several have now been done on saffron and depression:

The consistency across independent meta-analyses is reassuring. At the same time, reviewers repeatedly flag that many included trials were small, short, conducted in a single country, and sometimes funded by extract manufacturers — all of which can inflate apparent benefit. The signal is real and repeated, but it should be read as "promising and consistent," not "settled beyond doubt."

Back to Table of Contents

Add-On Use and SSRI Side Effects

Two lines of research look at saffron alongside conventional treatment rather than instead of it:

As an add-on. Talaei and colleagues (2015) tested crocin — saffron's main pigment — added on top of an antidepressant (fluoxetine, citalopram, or sertraline) in people with major depressive disorder. The crocin add-on group improved more than the placebo add-on group, hinting that saffron compounds may complement, not just imitate, standard drugs. This was a small pilot study and needs replication, but it is a mechanistically sensible direction.

For a specific drug side effect. A common and under-discussed reason people quit SSRIs is sexual dysfunction. Modabbernia and colleagues (2012) ran a randomized, double-blind, placebo-controlled trial of saffron in men experiencing fluoxetine-induced sexual impairment and found saffron improved some measures of erectile function compared with placebo. A parallel body of work has examined saffron for SSRI-related sexual dysfunction in women. These are niche findings, but they illustrate that saffron's role may include making established treatment more tolerable rather than replacing it.

Back to Table of Contents

Standardized Extracts and Newer Trials

Much of the newer research uses standardized, branded saffron extracts (one widely studied example is marketed as affron) that guarantee a fixed content of active compounds per dose. Standardization matters because saffron sold as threads varies enormously in strength depending on grade, storage, and — as the safety page details — whether it has been adulterated.

These trials broaden saffron's evidence beyond clinically diagnosed major depression into the large group of people with subthreshold low mood, everyday stress, and mild anxiety — the audience most likely to reach for a supplement in the first place. As always, several of these studies were manufacturer-supported, which is a reason to weigh them alongside, not above, the independent academic trials.

Back to Table of Contents

Practical Use, Dose, and Timing

The dose used in nearly every depression trial is remarkably consistent, which makes practical guidance easy to summarize:

If you are considering saffron for low mood, the sensible path is to treat it like any other active intervention: discuss it with your doctor or pharmacist, especially if you already take a prescribed antidepressant or other medication, and give it a fair, consistent trial of several weeks rather than a few days.

Back to Table of Contents

Honest Limitations of the Evidence

A fair reading of the saffron-depression literature has to acknowledge its weaknesses, because they shape how much confidence the results deserve:

None of this erases the positive signal — it is genuinely one of the better-supported herbal findings in psychiatry — but it does place a ceiling on how strongly the case should be stated.

Back to Table of Contents

Important Cautions

Back to Table of Contents

Key Research Papers

  1. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al. (2005). Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytotherapy Research. — PubMed PMID: 15852492
  2. Akhondzadeh S, Fallah-Pour H, Afkham K, et al. (2004). Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial. BMC Complementary and Alternative Medicine. — PubMed PMID: 15341662
  3. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, et al. (2005). Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression. Journal of Ethnopharmacology. — PubMed PMID: 15707766
  4. Moshiri E, Basti AA, Noorbala AA, et al. (2006). Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine. — PubMed PMID: 16979327
  5. Shahmansouri N, Farokhnia M, Abbasi SH, et al. (2014). A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. Journal of Affective Disorders. — PubMed PMID: 24289892
  6. Ghajar A, Neishabouri SM, Velayati N, et al. (2017). Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial. Pharmacopsychiatry. — PubMed PMID: 27701683
  7. Ahmadpanah M, Ramezani S, Bahmani D, et al. (2019). Crocus sativus L. (saffron) versus sertraline on symptoms of depression among older people with major depressive disorders. Psychiatry Research. — PubMed PMID: 31669837
  8. Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, et al. (2015). Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled pilot clinical trial. Journal of Affective Disorders. — PubMed PMID: 25484177
  9. Modabbernia A, Sohrabi H, Nasehi AA, et al. (2012). Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology. — PubMed PMID: 22552758
  10. Lopresti AL, Drummond PD, Inarejos-García AM, Prodanov M (2018). affron, a standardised extract from saffron for the treatment of youth anxiety and depressive symptoms: a randomised, double-blind, placebo-controlled study. Journal of Affective Disorders. — PubMed PMID: 29510352
  11. Kell G, Rao A, Beccaria G, et al. (2017). affron a novel saffron extract improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. Complementary Therapies in Medicine. — PubMed PMID: 28735826
  12. Hausenblas HA, Saha D, Dubyak PJ, Anton SD (2013). Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. Journal of Integrative Medicine. — PubMed PMID: 24299602
  13. Tóth B, Hegyi P, Lantos T, et al. (2019). The efficacy of saffron in the treatment of mild to moderate depression: a meta-analysis. Planta Medica. — PubMed PMID: 30036891
  14. Lopresti AL, Drummond PD (2014). Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Human Psychopharmacology. — PubMed PMID: 25384672

PubMed Topic Searches

  1. PubMed: Saffron depression randomized trials
  2. PubMed: Saffron vs fluoxetine
  3. PubMed: Saffron depression meta-analyses
  4. PubMed: Crocin antidepressant mechanism
  5. PubMed: Saffron anxiety and mood

Back to Table of Contents

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents